Mast cells are a critical component of the human immune system. Concentrated at the interface between the body and the external environment—the skin, gastrointestinal tract, respiratory mucosa, and lungs—they stand guard, releasing chemical compounds called mediators in response to perceived threats. Under normal circumstances, this is a protective mechanism. In mast cell activation syndrome (MCAS), that release becomes dysregulated, triggering inflammatory reactions throughout the body that can be difficult to trace to a single source.
MCAS is frequently mischaracterized—including by clinicians—as “histamine intolerance.” While histamine is one of the mediators released during mast cell activation, and histamine intolerance does exist as a distinct entity, conflating the two leads to incomplete assessment and suboptimal outcomes. Understanding the distinction, and addressing the root causes that drive mast cell dysregulation in the first place, is where functional medicine adds its greatest value.
What Are Mast Cells and What Do They Do?
Mast cells originate in the bone marrow and reside in tissues throughout the body. Each mast cell contains granules, which are tiny intracellular sacs that store upward of a hundred chemical mediators. When a trigger binds to the mast cell surface, those granules release their contents into the surrounding tissue in a process called degranulation.
Mediators released include histamine, tryptase, heparin, prostaglandins, leukotrienes, and cytokines, each producing distinct downstream effects. Histamine triggers vasodilation and increased vascular permeability. Tryptase, a proteolytic enzyme, can degrade nerve endings and extracellular matrix proteins. Prostaglandins and leukotrienes drive inflammatory cascades with systemic reach. The diversity of these mediators explains why MCAS can present so differently from patient to patient.
MCAS vs. Histamine Intolerance: An Important Clinical Distinction
Histamine intolerance arises when histamine accumulates faster than the body can degrade it. The primary degradation enzymes are diamine oxidase (DAO), which breaks down histamine in the gastrointestinal tract, and histamine-N-methyltransferase (HNMT), which acts intracellularly. When DAO activity is insufficient, typically due to gut inflammation, genetic variants, medication interference, or chronic dysbiosis, dietary and endogenous histamine builds up, producing a predictable cluster of symptoms.
MCAS involves a broader, more complex pathophysiology. The problem is not simply impaired histamine clearance but the dysregulated activation of mast cells themselves, releasing not just histamine but the full spectrum of inflammatory mediators. Patients with MCAS may react to triggers that have nothing to do with dietary histamine, such as heat, stress, exercise, odors, hormonal fluctuations, insect stings, and medications. The symptom picture is correspondingly more systemic and less predictable.
Both conditions can and do coexist, and addressing one without the other leaves meaningful pathology unresolved.
Clinical Presentation: When to Think MCAS
Because mast cells are distributed throughout the body, MCAS can affect virtually every organ system. This multi-system involvement is one of the primary reasons MCAS is underdiagnosed — symptoms that appear unrelated are rarely attributed to a common underlying mechanism. Patients often carry multiple diagnoses before MCAS is considered.
Symptom patterns to recognize include:
Systemic: Fatigue, widespread chemical and medication sensitivities
Gastrointestinal: Abdominal pain, bloating, nausea, heartburn, constipation, diarrhea, often with significant food reactivity. In one study examining patients with persistent IBS-like symptoms, 87% of those who tested positive for MCAS reported abdominal pain, with bloating, constipation, nausea, and reflux also highly prevalent. SIBO was found in 31% of those patients, suggesting mast cell mediators may directly alter GI motility.
Neurological: Headaches, migraines, impaired concentration and memory
Psychiatric: Anxiety, depression
Respiratory: Nasal congestion, asthma, throat swelling
Cardiovascular: Orthostatic hypotension, tachycardia, hypercoagulability
Musculoskeletal: Diffuse aches, bone pain, early osteoporosis
Skin: Flushing, urticaria, pruritus, temperature dysregulation
Genitourinary: Irritable bladder, interstitial cystitis
Published data suggest women represent approximately 69% of MCAS patients, and symptom onset often begins in childhood, yet the average time to diagnosis has been reported at 30 years. When a clinician notes multi-system symptomatology that doesn’t fit a single diagnosis, MCAS should be on the differential.
Root Cause Drivers: The Functional Medicine Lens
Functional medicine does not treat MCAS as an isolated diagnosis. The critical clinical question is: what is driving mast cell dysregulation in this individual?
Chronic infections. Both bacterial and viral pathogens can trigger mast cell degranulation as part of the immune response. Borrelia burgdorferi, the causative organism in Lyme disease, has been shown to directly activate mast cells. In clinical practice, a significant proportion of patients with tickborne infections also carry MCAS as a component of their immune dysregulation. Effective treatment of the underlying infection is part of resolving MCAS in these patients.
Mold and mycotoxin exposure. Environmental mold and mycotoxins are potent drivers of immune dysfunction and mast cell activation. Any patient with MCAS who has had exposure to water-damaged buildings warrants thorough mold illness evaluation. Addressing mycotoxin burden has measurable impact on MCAS outcomes.
Gut dysbiosis and intestinal permeability. The GI tract is one of the highest concentrations of mast cells in the body. Dysbiosis, SIBO, and intestinal permeability create a microenvironment that sustains mast cell activation. Histamine-producing bacteria further amplify histamine load. Healing the gut is not ancillary to MCAS management, it is foundational.
Environmental toxins and heavy metals. Herbicides, pesticides, and heavy metal accumulation have been implicated in mast cell sensitization. Toxin burden assessment is part of a thorough MCAS workup.
Genetic predisposition. Some patients have heritable variations that lower their threshold for mast cell activation or impair mediator clearance. This does not mean the condition is fixed; it means the patient requires a lower overall antigenic and toxic burden to remain below their symptomatic threshold.
Hormonal fluctuations. Estrogen promotes histamine release from mast cells. This explains the frequently observed worsening of MCAS symptoms perimenstrually, during perimenopause, or in the context of estrogen dominance. Progesterone has complex, context-dependent effects on mast cells, including reducing mast cell migration and proliferation in some contexts but promoting degranulation in others (particularly in uterine tissue). Whether progesterone provides symptom relief in women with MCAS during the luteal phase has not been systematically studied.
Functional Medicine Assessment
Diagnosing MCAS requires attention to both clinical pattern recognition and, where appropriate, laboratory evaluation. The Consensus 2 Criteria represent the most validated diagnostic framework currently available, but in clinical practice, testing is not always the straightforward confirmation it might seem, and it is not always the right starting point for every patient.
The core challenge is specimen handling. Most MCAS mediators are chemically unstable at room temperature, which means the integrity of results depends entirely on an unbroken cold chain from collection through processing. A 24-hour urine collection must be refrigerated throughout and transported in a cooler. Blood samples require chilled handling at the point of draw, something many standard labs are not set up to manage reliably. Samples collected during a symptomatic flare are more likely to capture elevated mediators, since mast cell degranulation is episodic and levels between flares may normalize. Even under optimal conditions, it is not uncommon for all markers to return within reference range in a patient with a clinically compelling presentation. A single elevated mediator is sufficient for diagnostic support in the right context, but a negative panel does not rule out MCAS.
For these reasons, formal mediator testing is not something we pursue in every patient. When a patient presents with a multi-system symptom picture consistent with MCAS, has identifiable triggers, and has not responded to conventional workup, a clinical diagnosis supported by a trial of treatment is a reasonable and accepted approach. In fact, response to antimediator therapy is itself one of the three pillars of MCAS diagnosis under current guidelines alongside episodic symptoms affecting at least two organ systems and elevated mast cell mediators captured during a symptomatic episode. Symptom response to mast cell-stabilizing strategies, dietary histamine reduction, and root cause treatment is diagnostically informative in its own right.
When laboratory assessment is pursued, the validated markers for MCAS are serum tryptase (ideally drawn within one to four hours of symptom onset, with an increase of more than 20% plus 2 ng/mL above baseline being the relevant threshold), 24-hour urine N-methylhistamine, 24-hour urine 11B-prostaglandin F2 alpha, and urine or serum leukotriene E4. All specimens require strict chilled handling.
For patients where histamine intolerance is a prominent clinical feature, serum DAO activity is sometimes considered as part of a broader assessment, but it is worth understanding its limitations. Research shows that only a minority of patients with suspected histamine intolerance actually demonstrate both elevated histamine and reduced DAO activity simultaneously, subjective symptom burden does not correlate reliably with serum histamine parameters, and DAO levels have limited sensitivity to dietary-driven histamine fluctuations. There are also no standardized reference ranges that have been validated across labs. DAO testing is not part of the diagnostic criteria for MCAS, and a normal result should not be interpreted as ruling out clinically significant histamine dysregulation. It is one data point among many, weighted accordingly.
A thorough root cause workup should include evaluation for Lyme disease and co-infections, mold illness (mycotoxin urine testing, HLA-DR genotyping), gut health via comprehensive stool analysis and SIBO breath testing, hormone assessment including estrogen metabolism where indicated, and MTHFR status, each selected based on the individual clinical picture rather than applied as a universal panel.
Functional Management Framework
Effective MCAS management is layered. Symptom mitigation through dietary, nutraceutical, and medication strategies provides meaningful relief and creates the stability needed to address underlying drivers.
Dietary modification. Reducing dietary histamine load is a primary intervention. High-histamine foods to limit include fermented foods (kombucha, kimchi, sauerkraut, miso), aged cheeses, cured meats, vinegar, tomatoes, eggplant, spinach, alcohol, tuna, sardines, anchovy, citrus, and chocolate. Histamine-liberating foods—including citrus, strawberries, pineapple, papaya, and peanuts—can also be problematic even when histamine content is low. The goal is not lifelong restriction but reducing total histamine burden while gut healing and root cause treatment proceed.
Gut repair. Restoring intestinal integrity and microbiome balance is central to both reducing histamine load and stabilizing mast cell activity. Strategies include targeted antimicrobial treatment where SIBO is confirmed, mucosal repair support with L-glutamine and phosphatidylcholine, and probiotic selection that avoids histamine-producing strains. Lactobacillus rhamnosus and Bifidobacterium infantis are better-tolerated options in this population.
Mast cell-stabilizing nutrients. Quercetin is a well-studied bioflavonoid that acts as a mast cell stabilizer, inhibiting both degranulation and the enzymatic conversion of histidine to histamine. Vitamin C supports DAO activity and also has mast cell-stabilizing properties; liposomal or buffered forms are better tolerated. These are typically used in combination for synergistic effect.
DAO enzyme support. For patients with prominent dietary histamine reactivity and evidence of DAO insufficiency, oral DAO supplementation before meals can reduce acute histamine uptake from food. This is a management tool rather than a root cause intervention, but it provides meaningful quality-of-life support while underlying drivers are addressed.
Methylation support. Histamine is degraded in part through methylation pathways. Patients with MTHFR variants or otherwise impaired methylation may have reduced histamine clearance. Methylated B12 (methylcobalamin) and 5-MTHF, alongside B6, support HNMT-mediated histamine degradation.
Medication management. For patients with moderate to severe MCAS, pharmaceutical support is often a necessary component of the management plan, particularly in the early stages before root cause treatment gains traction. The standard medication framework works across histamine receptor subtypes and mediator pathways.
H1 antihistamines block histamine at H1 receptors and are typically the first pharmacological layer. Non-sedating options such as cetirizine, loratadine, and fexofenadine are generally preferred for ongoing use. Sedating antihistamines like diphenhydramine can worsen cognitive symptoms and are better reserved for acute situations rather than daily use.
H2 antihistamines such as famotidine address histamine at H2 receptors, which are concentrated in the gastrointestinal tract and cardiovascular tissue. Adding an H2 blocker to an H1 antihistamine provides broader receptor coverage and is particularly useful when GI symptoms (reflux, nausea, cramping) are prominent.
Mast cell stabilizers, most notably cromolyn sodium, work upstream by inhibiting mast cell degranulation rather than blocking mediators after release. Oral cromolyn is used specifically for GI-dominant presentations and is poorly absorbed systemically, making it well-suited for patients whose primary symptom burden is in the gut. Ketotifen, where available, acts as both an H1 antihistamine and a mast cell stabilizer and is sometimes used when broader stabilization is needed.
Leukotriene receptor antagonists such as montelukast address the leukotriene arm of mast cell mediator release, which H1 and H2 antihistamines do not cover. For patients with respiratory symptoms, skin reactivity, or incomplete response to antihistamine therapy alone, adding leukotriene blockade can make a meaningful difference.
An important consideration in medication selection for this population is that many commonly used drugs, including NSAIDs, certain antibiotics, opioids, and some antidepressants, are themselves mast cell triggers or DAO inhibitors. A medication review is always warranted in MCAS patients, and new prescriptions should be introduced one at a time with careful observation for reactivity.
Addressing root causes. The sequence matters. Mast cell stabilization, dietary support, and medication management create a foundation, but durable improvement requires treating what is driving mast cell activation, whether that is Lyme disease and co-infections, mold illness, gut dysbiosis, or hormonal imbalance. Patients who address only symptoms without identifying and resolving root causes typically find their tolerance thresholds remain low and symptom flares recur. The important step is that many patients need to feel stable before their bodies can tolerate root cause treatments. It is very reasonable to stabilize and regulate mast cells first, before you start root cause treatments.
Clinical Takeaway
MCAS is a condition of systemic immune dysregulation, not simply a problem with histamine-rich foods. The clinician who approaches it through a root cause framework, asking why the mast cells are dysregulated, not just how to suppress their mediators. will achieve meaningfully better outcomes for these patients. The diagnostic and therapeutic tools exist. The challenge is applying them with enough specificity, and enough patience, to work through the layers this condition typically involves.
